Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses androgenetic alopecia and other types of hair loss in women, but reports no new results; the authors distinguish between AA with and without virilization.

This research aims to address gaps in understanding alopecia areata by evaluating the real-world effectiveness and safety of baricitinib, identifying predictors of therapeutic response, and exploring the long-term impact on life quality, including sexual health. Results are not reported in the abstract.

This study outlines treatment strategies for autoimmune alopecia areata, detailing that while mild cases may resolve on their own, severe cases often require intervention, with new JAK inhibitors like baricitinib and ritlecitinib emerging as promising treatments for those not responding to traditional therapies.

This study found that alopecia areata significantly impacts patients' quality of life irrespective of hair loss severity, and concluded that the newer assessment tools AAPPO and AASIS better capture this impact compared to the traditional SALT measure.

This study reported that the prevalence of alopecia areata in the US slightly increased from 0.199% to 0.222% between 2016 and 2019, with higher rates observed in women and adults.

This study found significant structural and compositional differences in hair affected by alopecia areata compared to healthy hair, using a range of physico-chemical investigation methods.

The Brazilian version of the Alopecia Areata Quality of Life Index is reliable for assessing patients' quality of life.

This review discusses emerging evidence on azathioprine's efficacy and safety for severe alopecia areata, reporting sustained response in many patients but emphasizing the need for controlled trials.

This review discusses the repurposing of auranofin for oncological and non-oncological uses and highlights its early-stage clinical trial findings, suggesting further exploration of its therapeutic potential.

Machine learning can use blood tests to help predict moderate-to-severe alopecia areata.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

This source presents an expert consensus framework for determining which Australian patients with alopecia areata should receive subsidized JAK inhibitor therapy, emphasizing the need for future research including patient perspectives to enhance criteria, ensure fair treatment access, and evaluate real-world outcomes.

In this study, researchers found that the AIRE G961C variant is a significant risk factor for severe alopecia areata and early-onset cases, particularly in patients with alopecia universalis.

Hair loss treatment caused more hair loss in a man.

AI can accurately measure hair loss severity in alopecia areata.

This study found that androgenetic alopecia is significantly more common in medical students compared to non-medical students in Peshawar, and its prevalence increases with academic progression, suggesting a possible link with stress or lifestyle factors.

This vodcast discusses various tools for assessing the severity of alopecia areata, emphasizing the importance of considering psychosocial impacts alongside physical symptoms.

This review highlights the variability and unpredictability of alopecia areata, ranging from single scalp patches to total body hair loss, and notes the 2022 approval of the first AA-specific drug, baricitinib, potentially spurring new research into targeted treatments.

In this study, the rs4541843 G > A variant was found to be significantly associated with increased risk and severity of alopecia areata, as well as elevated expression of hsa-miR-182-5p, suggesting their potential as molecular markers for diagnosis and severity assessment.

This study found that ultraviolet-induced fluorescence dermoscopy enhanced the identification of follicular openings in alopecia areata, potentially aiding in the assessment of disease severity and treatment strategies.

This study observed that patients with alopecia areata had decreased odds of developing stroke and a potential decreased risk of acute myocardial infarction, though the latter was not statistically significant.

In this study, combination therapy with cyclosporine and PUVA for severe alopecia areata resulted in a majority of patients showing only fair to poor responses, though some improvements were noted.

In this study, PA-011, a traditional Chinese medicine extract, was shown to improve hair growth in alopecia areata model mice by reducing skin inflammation and altering skin microbiota, indicating its potential therapeutic role for this condition.

This study found a significant association between alopecia areata and systemic lupus erythematosus, with a particularly strong link observed in children.

This study found that AA may have a protective role in the progression of both HBDC and CRC, suggesting potential new research avenues for treatments of these conditions.

This study found that alopecia areata significantly impacts both emotional and psychosocial well-being, leading to impaired productivity in adults and adolescents, especially those experiencing more extensive hair loss.

This study introduced a novel framework that significantly improves the accuracy of alopecia areata lesion segmentation in semi-supervised scenarios, outperforming existing methods and aiding in the disease's diagnosis, treatment, and staging, which can impact quality of life and mental well-being.

Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.

This study found that the SAAD-41 is a validated tool for assessing psychosocial outcomes in individuals with alopecia areata, showing strong correlations with established measures of quality of life and coping.